Borrelia garinii

Borrelia garinii is a spirochetal bacterium belonging to the Borrelia burgdorferi sensu lato complex, a group of pathogens responsible for Lyme borreliosis. It is a significant etiological agent of neuroborreliosis in Eurasia, particularly in regions of Europe and Asia. The organism is maintained in an enzootic cycle primarily involving Ixodes ricinus and Ixodes persulcatus ticks and various bird species as reservoir hosts. Its distinct genetic and antigenic profile differentiates it from other genospecies like Borrelia afzelii and Borrelia burgdorferi sensu stricto, influencing its clinical presentation and geographical distribution.

Microbiology and classification

Borrelia garinii is a helical, microaerophilic spirochete with a characteristic double-membrane structure and periplasmic flagella that confer its distinctive corkscrew motility. It was first validly described and named in 1992 by a team including Oleg Kahl, following extensive genetic analysis of the Borrelia burgdorferi sensu lato complex. Classification within the genus Borrelia is based on molecular methods, particularly multilocus sequence typing and analysis of conserved genes such as the 16S ribosomal RNA gene, the flagellin gene, and the outer surface protein A locus. Phylogenetically, it clusters distinctly from other Lyme disease-associated spirochetes like Borrelia bavariensis, which was later separated from B. garinii based on genomic studies. The species exhibits considerable genetic diversity, with multiple ribosomal RNA intergenic spacer types and plasmid profiles, which are studied at institutions like the Institut Pasteur and the Centers for Disease Control and Prevention.

Pathogenesis and clinical significance

The pathogenesis of Borrelia garinii infection is linked to its ability to disseminate from the site of the tick bite and evade the host immune system. It exhibits a pronounced neurotropism, making it the primary cause of Lyme neuroborreliosis in its endemic range. Clinical manifestations often include lymphocytic meningitis, radiculoneuritis, and cranial neuritis, such as Bell's palsy. Unlike Borrelia afzelii, which is more associated with acrodermatitis chronica atrophicans, B. garinii less frequently causes chronic arthritis. Its outer surface protein C is a major variable antigen involved in immune evasion, and specific lipoproteins can trigger inflammatory responses in the central nervous system, as researched at the Karolinska Institutet and the University of Vienna.

Epidemiology and transmission

The geographical distribution of Borrelia garinii spans temperate regions of Eurasia, with high prevalence reported in Central Europe, Scandinavia, Russia, and parts of East Asia. Its enzootic cycle is maintained between hard-bodied ticks of the Ixodes genus, primarily Ixodes ricinus in western Europe and Ixodes persulcatus in eastern Europe and Asia, and various reservoir hosts. Notably, bird species, including thrushes and blackbirds, are critical reservoirs, facilitating long-range dispersal of infected ticks, a phenomenon studied by the European Centre for Disease Prevention and Control. Human infection occurs through the bite of an infected nymph or adult tick during activities in endemic areas like the Black Forest or the Ural Mountains.

Diagnosis and detection

Diagnosis of Borrelia garinii infection relies on a combination of clinical evaluation, exposure history, and laboratory testing. The European Federation of Neurological Societies guidelines recommend a two-tier serological approach, typically starting with an enzyme-linked immunosorbent assay followed by confirmatory Western blot using specific antigens. However, cross-reactivity with other Borrelia species and Treponema pallidum can complicate interpretation. Direct detection methods include polymerase chain reaction targeting genes like ospA or the 5S-23S intergenic spacer region in cerebrospinal fluid samples from neuroborreliosis cases. Cultivation from clinical specimens is possible in specialized Barbour-Stoenner-Kelly medium but is slow and performed primarily in reference laboratories like the Robert Koch Institute.

Treatment and prevention

Standard treatment for Borrelia garinii infections involves antibiotic therapy, with regimens guided by organizations like the Infectious Diseases Society of America. For early localized disease, oral doxycycline, amoxicillin, or cefuroxime axetil are effective. For neuroborreliosis, intravenous administration of ceftriaxone or penicillin G for 14-28 days is recommended. Prevention focuses on avoiding tick bites in endemic areas through the use of DEET repellents, wearing protective clothing, and performing prompt tick checks. Environmental measures and public health initiatives by bodies such as the World Health Organization aim to raise awareness. Research into vaccine development continues, though no vaccine is currently available for the Eurasian genospecies.

Category:Spirochaetes Category:Bacteria described in 1992